Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 324 participants.

Also called NCT06643819

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 324 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06643819
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06643819. Randomized; double masking; primary purpose treatment. Start 2024-10-14 (actual); primary completion 2026-03-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A
Condition
Essential Hypertension
Intervention (Drug)
Sacubitril∙Valsartan(dose maintenance)
Intervention (Drug)
Sacubitril∙Valsartan(dose increasing)
Intervention (Drug)
Valsartan
Lead sponsor
Chong Kun Dang Pharmaceutical (class: industry)

Record details

Record id
cardio:ct-nct06643819
Content hash
f94d59fba9602821e51d327198cf99a1211bfd960fdc915df2d33d7abef636ad